Clinical trials: Mammary Cancer
Cancer, Breast, Cognitive Impairment
Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors
Purpose:To gather preliminary data and to determine the feasibility and acceptability of an 8-week Tai Chi intervention for adults cancer survivors (survivors) who report experiencing cognitive impairment, and to perform…
- Trial name
- NCT03196037
- Testing
- Tai Chi
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00014430
- Testing
- trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
High Risk for Invasive Breast Cancer
SHORTened Duration of TAMoxifen
The purpose of this study is to learn whether a shorter-duration, low-dose tamoxifen regimen can reduce the risk of developing breast cancer or breast cancer recurrence in post-menopausal women who are at increased risk for…
- Trial name
- NCT07806630
- Testing
- Tamoxifen, Tamoxifen (Nolvadex)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Rutgers, The State University of New Jersey
HER2-positive Breast Cancer
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced, unresectable, or metastatic…
- Trial name
- NCT03125928
- Testing
- Atezolizumab, Paclitaxel, Trastuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Brain Metastases
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and pyrotinib with fulvestrant in ER/PR positive and HER2-positive breast cancer patients with brain metastasis.
- Trial name
- NCT04334330
- Testing
- Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs.
- Trial name
- NCT00003253
- Testing
- paclitaxel, antitumor drug screening assay
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oncotech
Hormone Receptor Positive Early Breast Cancer
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole…
- Trial name
- SIE-1 (NCT07401381)
- Testing
- US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
- Where
- 21 sites in United States, Serbia and 1 more
- Volunteers
- 120 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Breast Cancer, Early-stage Breast Cancer
Cardiometabolic Screening Program
This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors.
- Trial name
- NCT05386719
- Testing
- Prescreening, Screening and Enrollment, Baseline
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Malignant Neoplasm, Breast Cancer
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases.
- Conditions
- Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
- Trial name
- NCT04503265
- Testing
- AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- AtlasMedx, Incorporated
Breast Cancer
Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer
This is a single-arm, single-center, prospective observational study. It uses offline PET/CT to verify and quantify the range accuracy of hypofractionated proton radiotherapy for postoperative breast cancer.
- Trial name
- OFFLINE-PET-PR (NCT07543107)
- Testing
- Offline PET/CT scanning
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with…
- Trial name
- SOPHIA (NCT02492711)
- Testing
- Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
- Where
- 167 sites in United States, Austria and 16 more
- Volunteers
- 624 people
- Sponsor
- MacroGenics
2D Speckle Tracking Echocardiography, Breast Cancer
Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients
The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained…
- Conditions
- 2D Speckle Tracking Echocardiography, Breast Cancer, Cardiac Magnetic Resonance
- Trial name
- NCT06206395
- Testing
- Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging
- Where
- Egypt
- Volunteers
- 190 people
- Sponsor
- Assiut University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04086875
- Testing
- Focus Group, Text Message, Best Practice
- Where
- 7 sites in United States
- Volunteers
- 332 people
- Sponsor
- Thomas Jefferson University
Breast Cancer
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Triple-negative breast cancer has always been a difficult problem in clinical practice because of its young onset age, high aggressiveness, no clear therapeutic target and poor clinical prognosis.
- Trial name
- NCT05749575
- Testing
- Chidamide Plus Toripalimab Plus Paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
This is an open-label, mono-center phase I/II study designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated…
- Trial name
- NCT00930475
- Testing
- RAD001 (Everolimus) in combination with carboplatin
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Charite University, Berlin, Germany
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
Breast Cancer
NEXT (Nutrition and EXercise During Adjuvant Treatment) Study
This study will offer a supervised exercise program and healthy eating education to women with breast cancer undergoing chemotherapy as a physician-referred program and measure the adoption, adherence and satisfaction with the…
- Trial name
- NExT (NCT01806181)
- Testing
- Exercise
- Where
- 2 sites in Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Breast Cancer
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8…
- Trial name
- NCT02297230
- Testing
- Radiation Therapy (RT), Capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Breast Cancer
Efficacy and Safety of 500mg of Fulvestrant
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness.
- Trial name
- NCT00585507
- Testing
- Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense.
- Trial name
- NCT00418236
- Where
- 37 sites in United States, Argentina and 12 more
- Volunteers
- 400 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.